Serum GPER-1 and Oxidant/Antioxidant Levels on Retinopathy in Diabetic Patients

NCT ID: NCT04930224

Last Updated: 2021-06-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-07-01

Study Completion Date

2020-04-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Observational, comparative, cross-sectional study

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study was conducted on G protein-mediated estrogen receptor 1 (GPER-1), which is thought to be effective in preventing the development of diabetic retinopathy (DR). There are studies proving that GPER-1 prevents neuroprotective effects and vascular pathology in many tissues. In the study, serum GPER-1 and oxidative stress biomarker levels were compared in diabetic patients and healthy control groups. GPER-1 was found to be significantly increased in diabetic patients. In addition, a positive correlation was found with oxidant markers. This may lead to new treatment models in the future.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus Diabetic Retinopathy Hormones

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Proliferative Diabetic retinopathy

40 patients with proliferative diabetic retinopathy

The effect of GPER-1 on the formation of diabetic retinopathy

Intervention Type DIAGNOSTIC_TEST

Demonstrating the neuroprotective effect of GPER-1 in the formation of diabetic retinopathy and being a guide for new treatment models

Non-Proliferative Diabetic retinopathy

40 patients with non-proliferative diabetic retinopathy

The effect of GPER-1 on the formation of diabetic retinopathy

Intervention Type DIAGNOSTIC_TEST

Demonstrating the neuroprotective effect of GPER-1 in the formation of diabetic retinopathy and being a guide for new treatment models

Healthy individuals

40 healthy persons

The effect of GPER-1 on the formation of diabetic retinopathy

Intervention Type DIAGNOSTIC_TEST

Demonstrating the neuroprotective effect of GPER-1 in the formation of diabetic retinopathy and being a guide for new treatment models

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

The effect of GPER-1 on the formation of diabetic retinopathy

Demonstrating the neuroprotective effect of GPER-1 in the formation of diabetic retinopathy and being a guide for new treatment models

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 40 individuals were required to have Proliferative Diabetic Retinopathy (PDR);
* 40 were required to have Non-PDR;
* 40 were required to be healthy, without any systemic disease.

Exclusion Criteria

* Glaucoma,
* Ocular trauma sequelae,
* Pathological myopia,
* Non-diabetic retinopathy,
* A history of previous ocular surgery,
* Endocrine disorders (e.g.,thyroidopathy, adrenal gland disorders, pituitary pathologies),
* Opacities interfering with fundus examination (e.g., corneal opacity, lens opacity, vitreous cloudiness other than diabetic haemorrhage).
Minimum Eligible Age

35 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kahramanmaras Sutcu Imam University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Abdullah Beyoğlu

Assist of Prof

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Abdullah Beyoğlu, MD

Role: STUDY_CHAIR

Kahramanmaras Sutcu Imam University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Abdullah Beyoğlu

Kahramanmaraş, None Selected, Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

(Project no: 2019/5-24 M

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.